Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

• Published in: The Lancet (British edition) Vol. 382; no. 9896; pp. 951 - 962
• Main Authors: Leucht, Stefan, Cipriani, Andrea, Spineli, Loukia, Mavridis, Dimitris, Örey, Deniz, Richter, Franziska, Samara, Myrto, Barbui, Corrado, Engel, Rolf R, Geddes, John R, Kissling, Werner, Stapf, Marko Paul, Lässig, Bettina, Salanti, Georgia, Davis, John M
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 14.09.2013; Elsevier; Elsevier Limited
• Subjects: Adult; Adult and adolescent clinical studies; adverse effects; Antipsychotic Agents - therapeutic use; Antipsychotics; Bias; Biological and medical sciences; chlorpromazine; Drug dosages; Food and Drug Administration; General aspects; guidelines; haloperidol; Health policy; Humans; Internal Medicine; Internet; Medical research; Medical sciences; Mental disorders; mental health; Meta-analysis; Neuropharmacology; odds ratio; patients; Pharmaceutical industry; Pharmacology. Drug treatments; prolactin; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Psychoses; Psychotropic drugs; randomized clinical trials; Randomized Controlled Trials as Topic; risk; Schizophrenia; Schizophrenia - drug therapy; sedation; Sensitivity analysis; Side effects; Statistical analysis; Studies; Systematic review; Treatment Outcome; United States; weight gain; United States; United States > US; Psychosis; Medicine; Chemotherapy; Treatment; Multiple; Neuroleptic; Psychotropic; Treatment efficiency; Schizophrenia; Antipsychotic; Comparative study; Metaanalysis

The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative...